Suzanne C. Van Es
Groningen, GR, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
[89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell Carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 09, 2022
Correction to: [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer.
Journal: European journal of nuclear medicine and molecular imaging
Published: June 15, 2020
Assessment of Bone Lesions with 18F-FDG PET Compared with 99mTc Bone Scintigraphy Leads to Clinically Relevant Differences in Metastatic Breast Cancer Management.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: March 06, 2020
Decalcification of Breast Cancer Bone Metastases With EDTA Does Not Affect ER, PR, and HER2 Results.
Decalcification of Breast Cancer Bone Metastases With EDTA Does Not Affect ER, PR, and HER2 Results.
Journal: The American journal of surgical pathology
Published: July 09, 2019
[89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer.
Journal: European journal of nuclear medicine and molecular imaging
Published: June 23, 2019
Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma.
Journal: European journal of nuclear medicine and molecular imaging
Published: January 29, 2019
RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancer.
Journal: Molecular oncology
Published: December 27, 2018
Comparative biodistribution analysis across four different 89Zr-monoclonal antibody tracers-The first step towards an imaging warehouse.
Journal: Theranostics
Published: March 29, 2018
89Zr-Bevacizumab PET: Potential Early Indicator of Everolimus Efficacy in Patients with Metastatic Renal Cell Carcinoma.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: September 01, 2016
Translation of New Molecular Imaging Approaches to the Clinical Setting: Bridging the Gap to Implementation.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: February 03, 2016
Balancing treatment efficacy, toxicity and complication risk in elderly patients with metastatic renal cell carcinoma.
Journal: Cancer treatment reviews
Published: December 10, 2015
89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: December 06, 2014
Showing 1-12 of 12
Last Updated: 09/26/2026